GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute of Allergy and Infectious Diseases (NIAID). The grant supports development of natural repertoire recombinant intravenous immunoglobulin (rIVIG) “hyperimmunes” against common pathogens for patients with primary immune deficiency (PID).

Read the full press release.

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods” and will take place during the Engineering Antibodies conference at 11:25 a.m. EDT on May 2, 2018, at the Seaport World Trade Center in Boston, Mass.

 

Read the full press release.

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in California. The presentation titled “Copying and Mining Complete Immune Systems” will take place at 9:00am Pacific time, on Friday, October 7, 2016.

Read the full press release.

 

 

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, Colo., and the second, “Antibodies as Drugs: Translating Molecules into Treatments,” will be held Feb. 25-March 1 in Whistler, British Columbia.

Read the full press release.

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming issue.

Read the full press release.

GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library,” is available online and will appear in the upcoming issue of the peer-reviewed scientific journal mAbs.

Read the full press release.

GigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the use of autologous TIL to fight a range of cancers.

Read the full press release.

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here.

GigaGen’s newly published data details the technical foundation of its approach for the affinity maturation of monoclonal antibodies discovered via its leading single-cell microfluidic technology platform, Surge. Affinity maturation is commonly used for antibody optimization when developing new drugs. The company is leveraging this technology platform for the development of monoclonal antibodies with unique binding and affinity profiles against selected oncology targets.

David Johnson, Ph.D., MBA, co-founder and chief executive officer of GigaGen, commented, “Often, antibodies need to be further engineered through ‘affinity maturation’ to achieve the appropriate affinities and kinetics that translate into in vivo efficacy. While this process can be important for antibody drug development, there are no universally accepted protocols for efficient and high-performance antibody affinity maturation. Our study is one of the most thorough evaluations of affinity maturation methods ever published. We have used knowledge from our work to develop novel antibody therapeutics with unique profiles against selected oncology targets, such as CTLA-4, with the potential to result in enhanced efficacy and safety profiles versus current antibody drug alternatives.”

Read the full press release.

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), Waisman Biomanufacturing and Goodwin Biotechnology, Inc.

Large scale production of GIGA-2050 will support an Investigational New Drug application (IND) and Phase 1 studies in COVID-19 patients. The GMP product will be subjected to nonclinical GLP toxicology and pharmacokinetics studies in fall 2020 and the company expects to reach the clinic in early 2021.

Read the full press release.

With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health system by requiring less inpatient care. Drugs that are more potent per gram could be priced competitively with lower-potency incumbents, increasing profits for the manufacturer and decreasing infusion times for the patient. Processes that are difficult to scale, such as cell therapy manufacturing, will become increasingly streamlined, allowing manufacturers to reduce prices while increasing profits.”

Read the full story.